Urinary renal epithelial cells can be used for NPHP1 phenotyping and a personalized therapeutic strategy
Journal of Cell Science · 2025
DOI: 10.1242/jcs.264141 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cell Science, 2025. Verfasst von Praveen Dhondurao Sudhindar und 10 weiteren Autor:innen. Beteiligte Einrichtung: Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Central Parkway, Newcastle upon Tyne, NE1 3BZ, UK. Hauptthemen laut MEDLINE: Epithelial Cells, Kidney Diseases, Cystic, Precision Medicine, Kidney. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 77 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Horizon European Union, Medical Research Council, PKD Charity.
Abstract (Originalsprache)
Nephronophthisis (NPHP) is a recessive tubulointerstitial nephropathy and a leading genetic cause of kidney failure in children and young adults. The most common genetic cause is a homozygous deletion of NPHP1, which encodes nephrocystin-1, a protein essential for primary cilium structure and cell junctions. Using personalized medicine and deep phenotyping, we investigated a family with three siblings carrying a homozygous NPHP1 deletion. We compared kidney biopsy tissue and human urine-derived renal epithelial cells (hURECs) from these individuals. Bulk RNA-seq on patient hURECs revealed altered expression in EGFR signalling, extracellular components and adherens junctions, which is consistent with the known roles for nephrocystin-1. Treatment with alprostadil, a proposed NPHP therapy, increased ciliation but worsened ciliary elongation. By contrast, the EGFR kinase inhibitor AG556 rescued of ciliary length and morphology. Transcriptional profiling post-treatment showed AG556 reversed the disease signature more effectively that alprostadil. These findings suggest that EGFR inhibition might offer a more promising therapeutic strategy for NPHP1-associated renal ciliopathy, warranting further testing in in vivo models before clinical application.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Central Parkway, Newcastle upon Tyne, NE1 3BZ, UK.
- Center for Human Genetics, Cliniques Universitaires Saint-Luc, Brussels, Belgium.
- Biosciences Institute, Faculty of Medical Sciences, Newcastle University, Central Parkway, Newcastle upon Tyne, NE1 3BZ, UK.
- Royal Victoria Infirmary, Newcastle upon Tyne, NE2 4LP, UK.
- Renal Services, Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, NE7 7DN, UK.
- NIHR Newcastle Biomedical Research Centre, Newcastle upon Tyne, NE4 5PL, UK.
ORCID-Profile: Eric Olinger, Zachary T Sentell, Holly Mabillard, Dominic Rutland, John A Sayer, Juliana E Arcila-Galvis
Förderung
- Horizon European Union
- Medical Research Council
- PKD Charity
- Kidney Research UK
- Northern Counties Kidney Research Fund
- Newcastle University
- LifeArc
- Swiss National Science Foundation
Zitieren
APA
Sudhindar, P. D., Olinger, E., Sentell, Z. T., Mabillard, H., Dicka, B., Wood, K., Rutland, D., Collins, C., Trevisan-Herraz, M., Sayer, J. A., & Arcila-Galvis, J. E. (2025). Urinary renal epithelial cells can be used for NPHP1 phenotyping and a personalized therapeutic strategy. Journal of Cell Science. https://doi.org/10.1242/jcs.264141
Vancouver
Sudhindar PD, Olinger E, Sentell ZT, Mabillard H, Dicka B, Wood K, et al. Urinary renal epithelial cells can be used for NPHP1 phenotyping and a personalized therapeutic strategy. Journal of Cell Science. 2025. doi:10.1242/jcs.264141
BibTeX
@article{Sudhindar2025,
author = {Sudhindar, Praveen Dhondurao and Olinger, Eric and Sentell, Zachary T and Mabillard, Holly and Dicka, Barbora and Wood, Katrina and Rutland, Dominic and Collins, Catherine and Trevisan-Herraz, Marco and Sayer, John A and Arcila-Galvis, Juliana E},
title = {Urinary renal epithelial cells can be used for NPHP1 phenotyping and a personalized therapeutic strategy},
journal = {Journal of Cell Science},
year = {2025},
doi = {10.1242/jcs.264141}
}
EUVIMED